Overview

Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE)

Status:
Completed
Trial end date:
2020-12-16
Target enrollment:
Participant gender:
Summary
This is a randomized, three-arm, open-label, clinical trial of malaria chemoprevention in children with sickle-cell anemia (SCA) at a single site in Homa Bay, Kenya. The study will enroll 246 children under 10 years of age, randomize participants 1:1:1 to one of three malaria chemoprevention regimens, and follow participants monthly for 12 months in order to record clinical episodes of malaria or SCA-related morbidity. Analyses will compare the efficacy of each regimen to prevent malaria and SCA morbidity.
Phase:
Phase 4
Details
Lead Sponsor:
Duke University
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Amodiaquine
Artemisinins
Artenimol
Dihydroartemisinin
Piperaquine
Proguanil
Sulfadoxine